Current Hepatitis Reports

, Volume 12, Issue 2, pp 119–123

Current Management of HBV Pre and Post Liver Transplant

Hepatitis B: Therapeutics (P Martin and WG Cooksley, Section Editors)

DOI: 10.1007/s11901-013-0169-3

Cite this article as:
McCaughan, G.W. Curr Hepatitis Rep (2013) 12: 119. doi:10.1007/s11901-013-0169-3
  • 128 Downloads

Abstract

The introduction of the new DAAs Entecavir and Tenofovir have had a major impact on liver transplant for hepatitis B virus (HBV) infection. These agents have been shown to rescue patients with decompensated HBV in a manner similar to Lamivudine but without the same concern about resistance. The use of these agents post liver transplant with HBIG reduce HBV recurrence to <1 %. Increasingly they are being used to reduce long term use of HBIG although the timing of HBIG withdrawal and whether it should be applied to all HBV infected recipients requires further study.

Keywords

Hepatitis B virusLiver transplantationLamivudineAdefovirEntecavirTenofovirHBIGDecompensated cirrhosisOrgan donationHepatitis delta virusHepatocellular carcinoma

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.The Australian National Liver Transplant Unit, The AW Morrow Gastroenterology and Liver Centre, The Centenary Research InstituteRoyal Prince Alfred and the University of SydneyCamperdownAustralia